Jeffrey Field, M.S., Mba Email & Phone Number

Windermere, Florida, Us

One Less Broken Heart is a private 501(c)(3) nonprofit charitable organization dedicated to supporting research and families with children living with rare diseases. The Founder is also a Father of six (6) adopted daughters from Southeast Asia and his two youngest children both have very rare health conditions, and they are his inspiration for starting the foundation. One Less Broken Heart's fundraising activities will be focused on supporting the much-needed research required to drive the innovation necessary to help children where little or no treatments currently exists. In addition, many parents don't have the financial means to bring their children to Centers of Excellence to receive the specialized care that their children need. The foundation is also committed to supporting these families to help them get the care they deserve. The three (3) areas of focus for One Less Broken Heart includes: (1) Rare Complex Congenital Heart Disease (2) Rare Cancers and (3) Rare Genetic Diseases, with an emphasis on rare neurogenetic diseases.

Boston, Ma, Us

Boston Children's Hospital Trust"Until Every Child is Well."

San Carlos, California, Us

Clear Labs is the market leader in Next-Generation Sequencing (NGS) Automation Workflow solutions. The Clear Dx platform seamlessly integrates DNA sequencing, robotic automation, and cloud-based analytics that offers laboratories a fully automated end-to-end NGS workflow solution. The Clear Dx platform offers both diagnostic screening (Dx mode) and whole genomic sequencing (WGS mode) capabilities. The Dx screening mode enables laboratories to do to both diagnostic screening and simultaneous genomic surveillance to track infection clusters and subtyping for real-time contact tracing, as well as reporting on mutations and antimicrobial resistance, with a TAT of ~10 hours and a price comparable to qPCR. In addition, fully automated WGS can also be performed on the platform with an actionable TAT of less than 24 hours. Since the Clear Dx platform is an automated end-to-end NGS workflow solution (yes, no more tedious manual library preparation with existing NGS instruments), the Clear Labs NGS platform reduces lab tech labor costs and increases worker productivity. It takes ~30 minutes to load to load the samples and reagents, and after the lab tech pushes "start", they can walk away and work on other laboratory tasks while the Clear Dx system is doing all the work!

San Diego, Ca, Us

1. Played a key role in supporting the CEO in raising $45M (Series B and Series C)2. Signed a global strategic partnership with Illumina (leading to acquisition), including a global co-marketing agreement, a co-development agreement for targeted enrichment reagents, and a global distribution agreement for the first pan-pathogen targeted NGS enrichment panel for respiratory tract infections.Founding member of the IDbyDNA Commercial Team. IDbyDNA is transforming metagenomics by powering science and medicine to improve health by decoding the unknown. IDbyDNA is building the "Metagenomics Operating System of Disease Intelligence" and developing a global network to transform health. The Explify metagenomics technology platform, along with its proprietary hybrid-capture probe enrichment reagents, now enables laboratories to overcome the limitations of conventional infectious disease testing. For the first time, it is now possible to obtain greater clinical insights by leveraging the power of next-generation sequencing and simultaneously detect hundreds of pathogens, hundreds of genetic markers of anti-microbial resistance (AMR), and pathogen quantification, all within a single, more streamlined workflow with a 24-hour turnaround time, at price comparable to conventional ID testing methods (multiplex PCR panels).

Founding member of the GenePeeks Commercial Team:GenePeeks is a genetic information company with a mission to help families protect the health of future generations from rare autosomal recessive diseases. The Company's patented technology analyzes over 1,000+ rare genetic diseases of a "future" child’s genetic profile, identifying disease risk impossible to observe with existing pre-conception screening tools (such as Carrier Screening). The software digitally integrates Next-Gen sequencing data from two prospective parents, simulating genetic recombination and reduction that occurs naturally in human reproduction. This novel process of genetic risk assessment generates analytic targets that includes tens of thousands of “virtual genomes.”Played a key role in closing the Company's $16M Series B round of financing.

Switzerland 🇨🇭 , Ch

Founding member of the Foundation Medicine Commercial Team (Acquired by Roche):Responsible for building and leading the U.S. sales team for the commercialization of the first comprehensive genomic profiling assays for all types of solid and hematologic cancers; FoundationOne and FoundationOne Heme.Acquired by Roche for $ 5B

Irving, Texas, Us

Founding member:Played a key role in building the company's business unit since its inception in 2008. Held numerous VP-level roles during my tenure:1. Vice President, Oncology Strategic/Corporate Accounts2. Vice President, Oncology/Hematology Registry & Biorepository Research Network3. Vice President, Oncology National Accounts4. Regional Vice President, Oncology/Hematology Sales5. Regional Vice President, Business Development, Oncology Pharmaceutical Services6. $750M acquisition of Caris Dx (Anatomical Pathology Business Unit) by Miraca Life Sciences

Woonsocket, Ri, Us

Responsible for the management of the Pharmaceutical Services Sales team (20 people) and $100M and annual revenue. The Pharmaceutical Services team was responsible for contracting with pharmaceutical companies for therapeutic interchange and drug utilization management programs designed to maximize formulary compliance of the Preferred Drug List (PDL). 1. Advance Paradigm acquired PCS Health Systems from Rite Aid for $650M to form AdvancePCS2. AdvancePCS acquired by Caremark for $7.4B3. Caremark acquired by CVS Corporation for $27B to form CVS Caremark Corp., and later changed its name to CVS Health

Cambridge, Cambridgeshire, Gb

One of the initial founding employees of AstraZeneca since its original inception as a JV start-up between Merck & Co., Inc. and AB Astra of Sweden. Held numerous roles during my tenure:1. National Account Director, Managed Care (Formerly Astra Merck, Inc.)2. Regional Account Director, Managed Care (Formerly Astra Merck, Inc.)3. Business Unit Manager (Formerly Astra Merck, Inc.)4. Cardiovascular Medical Science Liaison (Formerly Astra Merck, Inc.)5. Pharmaceutical Sales Specialist (Formerly Astra Merck Group of Merck & Co., Inc.)AstraZeneca was initially started as a new division of Merck known as Astra Merck Group of Merck & Co., Inc. After specific commercial milestones were achieved as outlined in the JV agreement, this division was spun-off from Merck, and Astra Merck, Inc. (AMI) was created as a formal 50-50 JV between Merck and AB Astra. AMI was a separate corporation for 6 years, at which, Merck divested their 50% ownership interest to AB Astra for $10B. AMI was merged with Astra Pharmaceuticals USA, and 6 months later, AstraZeneca was formed when Astra and Zeneca announced their plans for the industry's next big pharma mega merger.

Rahway, New Jersey, Us

Responsible for selling a wide variety of pharmaceutical prescription products in multiple therapeutic areas including, hypertension, hyperlipidemia, hypercholesterolemia, and atherosclerosis, gastrointestinal diseases (DU, GU, GERD, ZE Syndrome), Rheumatoid arthritis, Osteoarthritis, and various pediatric vaccines.Received the Vice President's Club Award in 1991 for top national sales performance, and multiple Regional/District Awards for top sales performance in 1990, 1991, 1992.

Lawrence Township, Nj, Us

Worked in drug development as a synthetic organic chemist. My drug discovery efforts were focused in cardiovascular and metabolic diseases such as hyperlipoproteinemia, hypercholesterolemia, and atherosclerosis. Specifically, I worked on the development of HMG CoA Reductase inhibitors, Mevelonate Decarboxalase inhibitors, anti-oxidants, and other inhibitors of the biosynthesis of cholesterol. My research activities lead to patents in the U.S., Europe, Canada, and Japan. I was the first non-PhD chemist to ever be listed as a co-inventor on a BMS patent.

Master'S Of Science (M.S.), Organic Chemistry

Master'S Of Business Administration (Mba), Executive Management

Certification, Pharmacoeconomics/Pharmaceutical Economics

Bachelor'S Of Science (B.S.), Chemistry

High School Diploma